Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Guangzhou Lupeng Pharmaceutical Company LTD.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
69High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06357676CT.gov Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial | — | Recruiting | — | — | — |
NCT06482684CT.gov CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma | — | Recruiting | — | — | — |
NCT05864742CT.gov Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05431179CT.gov A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma | — | Withdrawn | — | — | — |
NCT05564052CT.gov A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT04802590CT.gov Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04662255CT.gov Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | — | Active Not Recruiting | — | — | — |
NCT04665115CT.gov Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) | — | Withdrawn | — | — | — |
NCT04477486CT.gov Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT03617484CT.gov Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma | — | Withdrawn | — | — | — |
Show 54 more trialsShow fewer
NCT03282396CT.gov Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04234061CT.gov Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04043845CT.gov ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | — | Withdrawn | — | — | — |
NCT03232307CT.gov Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma | — | Withdrawn | — | — | — |
NCT03190330CT.gov A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion | — | Completed | — | — | — |
NCT03939182CT.gov Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT03710772CT.gov Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03877055CT.gov A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT03219047CT.gov Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT03684694CT.gov Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma | — | Terminated | — | — | — |
NCT03478514CT.gov Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03323151CT.gov A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT03476655CT.gov Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India | — | Completed | — | — | — |
NCT03479268CT.gov Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03440567CT.gov Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT03088878CT.gov A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies | — | Completed | — | — | — |
NCT03295240CT.gov The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT03153202CT.gov Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | — | Active Not Recruiting | — | — | — |
NCT03112174CT.gov Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) | — | Completed | — | — | — |
NCT02950220CT.gov Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT02927964CT.gov TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma | — | Completed | — | — | — |
NCT02869633CT.gov Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant | — | Completed | — | — | — |
NCT02991638CT.gov Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers | — | Unknown | — | — | — |
NCT02743546CT.gov Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma | — | Withdrawn | — | — | — |
NCT02736617CT.gov Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT02858258CT.gov ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma | — | Unknown | — | — | — |
NCT02682641CT.gov Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL | — | Active Not Recruiting | — | — | — |
NCT03425591CT.gov A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice | — | Completed | — | — | — |
NCT02756247CT.gov A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma | — | Completed | — | — | — |
NCT02735876CT.gov A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | — | Withdrawn | — | — | — |
NCT02558816CT.gov A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients | — | Completed | — | — | — |
NCT02356458CT.gov Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma | — | Terminated | — | — | — |
NCT02471391CT.gov ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) | — | Unknown | — | — | — |
NCT02446236CT.gov Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT02303392CT.gov Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT02427620CT.gov Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT02419560CT.gov Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL | — | Completed | — | — | — |
NCT02460276CT.gov A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT02242097CT.gov Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT02268851CT.gov A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL | — | Completed | — | — | — |
NCT02109224CT.gov Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection | — | Terminated | — | — | — |
NCT02159755CT.gov Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT02169180CT.gov Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT01479842CT.gov Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | — | Active Not Recruiting | — | — | — |
NCT02013128CT.gov Ublituximab + Ibrutinib in Select B-cell Malignancies | — | Completed | — | — | — |
NCT01955499CT.gov Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT01804686CT.gov A Long-term Extension Study of PCI-32765 (Ibrutinib) | — | Recruiting | — | — | — |
NCT01880567CT.gov Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT01776840CT.gov A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT01646021CT.gov Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy | — | Completed | — | — | — |
NCT01599949CT.gov A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy | — | Completed | — | — | — |
NCT01236391CT.gov Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) | — | Completed | — | — | — |
NCT01109069CT.gov Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia | — | Completed | — | — | — |
NCT01833039CT.gov An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | — | Approved For Marketing | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mantle Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ibrutinib (this asset) | Guangzhou Lupeng Pharmaceutical Company LTD. | Approved | BB · 67 |
| Etoposide | Ruijin Hospital | P4 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Busulfanum | City of Hope Medical Center | P2 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BBB |
| Vincristine Sulfate | M.D. Anderson Cancer Center | P2 | BBB |
| Irinotecan | University of Michigan Rogel Cancer Center | P2 | BBB |
| Cediranib | City of Hope Medical Center | P2 | BB |
| Cyclophosphamide | Miltenyi Biomedicine GmbH | P4 | BB |
+42 more in the Mantle Cell Lymphoma cohort
Other indications for Ibrutinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoid Leukemia | — | P4 | BBB · 72 |
| Waldenstrom Macroglobulinemia | — | P4 | BB · 70 |
| B-Cell Chronic Lymphocytic Leukemia | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ibrutinib in Mantle Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ibrutinib-mantle-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →